Gapping up
News:
- DAWN +67.7% (Initial Data from Pivotal FIREFLY-1 Trial of Tovorafenib (DAY101) in Relapsed Pediatric Low-Grade Glioma)
- GRCL +12.1% (Presents Updated Clinical Data for BCMA/CD19 Dual-targeting FasTCAR GC012F in RRMM at EHA2022 Congress, Highlighting 100% MRD Negativity Rate in All Treated Patients)
- VXX +6.1% (trading higher with US futures down over 2%+)
- CHH +5% (acquires Radisson Hotel Group Americas for $675 mln)
- OPTN +2.7% (top-line results of ReOpen2, its second phase 3 clinical trial of XHANCE for treatment of chronic sinusitis)
- IONS +2.6% (treatment for Angelman syndrome receives orphan drug and rare pediatric disease designations from U.S. FDA)
- APLS +2.3% (receives FDA orphan designation for Pegcetacoplan, treatment of immune complex-membranoproliferative glomerulonephritis)
- MUDS +0.7% (Blue Nile to combine with Mudrick Capital Acquisition Corporation II )
- SKIL +0.6% (to sell SumTotal to Cornerstone for $200 mln)
Analyst comments:
- EDU +9.8% (upgraded to Overweight from Neutral at JP Morgan)
